Verastem Oncology宣布管理变革

2025-12-16 05:34

Verastem Oncology (NASDAQ:VSTM) announced on Monday strategic leadership changes to accelerate its next phase of growth.
John Johnson has been appointed as chairman of the board of directors, succeeding Michael Kauffman.
Kauffman has been appointed as the President of development.
Matthew Ros, COO, will be departing from the organization as the company transitions his responsibilities across the executive team.
The company also stated that it has completed the additional patient enrollment for RAMP 301, its international Phase 3 confirmatory trial in recurrent LGSOC.
Johnson brings more than three decades of experience across corporate strategy, operations, investing, clinical development, and oncology drug commercialization. He most recently served as Executive Chairman at Applied Therapeutics. Johnson also previously was the CEO of Reaction Biology, a global contract research organization.
Kauffman has an in-depth understanding of the company’s strategy, clinical development plans, and operations. Previously, Kauffman served as the CEO of Nereid Therapeutics.

More on Verastem